CA3109769A1 - Use of riluzole oral disintigrating tablets for treating diseases - Google Patents
Use of riluzole oral disintigrating tablets for treating diseases Download PDFInfo
- Publication number
- CA3109769A1 CA3109769A1 CA3109769A CA3109769A CA3109769A1 CA 3109769 A1 CA3109769 A1 CA 3109769A1 CA 3109769 A CA3109769 A CA 3109769A CA 3109769 A CA3109769 A CA 3109769A CA 3109769 A1 CA3109769 A1 CA 3109769A1
- Authority
- CA
- Canada
- Prior art keywords
- riluzole
- bhv
- pbo
- cancer
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862764864P | 2018-08-16 | 2018-08-16 | |
| US62/764,864 | 2018-08-16 | ||
| PCT/US2019/046709 WO2020037152A1 (en) | 2018-08-16 | 2019-08-15 | Use of riluzole oral disintigrating tablets for treating diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3109769A1 true CA3109769A1 (en) | 2020-02-20 |
Family
ID=69525906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3109769A Pending CA3109769A1 (en) | 2018-08-16 | 2019-08-15 | Use of riluzole oral disintigrating tablets for treating diseases |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210315865A1 (https=) |
| EP (1) | EP3836922B1 (https=) |
| JP (2) | JP2021534160A (https=) |
| KR (1) | KR20210045423A (https=) |
| CN (1) | CN112584831A (https=) |
| AU (1) | AU2019322889A1 (https=) |
| BR (1) | BR112021002692A2 (https=) |
| CA (1) | CA3109769A1 (https=) |
| EA (1) | EA202190544A1 (https=) |
| ES (1) | ES2987802T3 (https=) |
| IL (1) | IL280657A (https=) |
| MX (2) | MX2021001563A (https=) |
| PH (1) | PH12021550218A1 (https=) |
| SG (1) | SG11202100880VA (https=) |
| WO (1) | WO2020037152A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230027189A (ko) * | 2020-06-24 | 2023-02-27 | 바이오하벤 테라퓨틱스 리미티드 | 강박 장애를 치료하기 위한 조성물 및 방법 |
| EP4240308A4 (en) * | 2020-10-05 | 2024-10-30 | Icahn School of Medicine at Mount Sinai | Riluzole for the treatment of alzheimer's disease |
| WO2022103638A1 (en) | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Cannabinoids in the treatment of autism spectrum disorder |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| CN114177153B (zh) * | 2021-12-20 | 2023-04-07 | 平顶山市第二人民医院 | 一种利鲁唑口崩片及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| MXPA05005528A (es) * | 2002-11-26 | 2006-04-05 | Alk Abello As | Producto farmaceutico de alergeno. |
| US9241902B2 (en) * | 2003-12-17 | 2016-01-26 | R.P. Scherer Technologies, Llc | Chewable soft capsules containing ungelatinized starch |
| US8778979B2 (en) * | 2005-04-05 | 2014-07-15 | Yale University | Glutamate agents in the treatment of mental disorders |
| US20080260823A1 (en) * | 2007-04-20 | 2008-10-23 | Sciele Pharma, Inc. | Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea |
| PT2467372T (pt) * | 2009-08-10 | 2016-08-23 | Teva Pharma | Tratamento de distúrbios relacionados com bdnf usando laquinimod |
| US9041556B2 (en) | 2011-10-20 | 2015-05-26 | Apple Inc. | Method for locating a vehicle |
| US9434704B2 (en) * | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
| EA038518B1 (ru) * | 2014-11-21 | 2021-09-09 | Биохэйвен Фармасьютикал Холдинг Компани Лтд. | Сублингвальный препарат рилузола |
| MX2017006454A (es) * | 2014-11-21 | 2018-03-23 | Biohaven Pharm Holding Co Ltd | Administracion sublingual de riluzol. |
| WO2016085998A1 (en) * | 2014-11-26 | 2016-06-02 | Medicinova, Inc. | Combination of ibudilast and riluzole and methods of using same |
| RS62915B1 (sr) * | 2015-03-03 | 2022-03-31 | Biohaven Therapeutics Ltd | Prolekovi riluzola i njihova primena |
| JP2020506231A (ja) * | 2017-01-31 | 2020-02-27 | パオロ エル マンフレディ | 神経系の障害並びにその症状及び徴候の処置又は予防のため並びに疾患及び細胞の老化並びにその症状及び徴候に対する細胞保護のための化合物 |
-
2019
- 2019-08-15 WO PCT/US2019/046709 patent/WO2020037152A1/en not_active Ceased
- 2019-08-15 BR BR112021002692-4A patent/BR112021002692A2/pt not_active Application Discontinuation
- 2019-08-15 EA EA202190544A patent/EA202190544A1/ru unknown
- 2019-08-15 CA CA3109769A patent/CA3109769A1/en active Pending
- 2019-08-15 KR KR1020217007246A patent/KR20210045423A/ko not_active Ceased
- 2019-08-15 MX MX2021001563A patent/MX2021001563A/es unknown
- 2019-08-15 CN CN201980054201.0A patent/CN112584831A/zh active Pending
- 2019-08-15 JP JP2021507740A patent/JP2021534160A/ja active Pending
- 2019-08-15 US US17/268,072 patent/US20210315865A1/en active Pending
- 2019-08-15 ES ES19849456T patent/ES2987802T3/es active Active
- 2019-08-15 EP EP19849456.9A patent/EP3836922B1/en active Active
- 2019-08-15 SG SG11202100880VA patent/SG11202100880VA/en unknown
- 2019-08-15 AU AU2019322889A patent/AU2019322889A1/en not_active Abandoned
-
2021
- 2021-01-28 PH PH12021550218A patent/PH12021550218A1/en unknown
- 2021-02-04 IL IL280657A patent/IL280657A/en unknown
- 2021-02-08 MX MX2024007642A patent/MX2024007642A/es unknown
-
2023
- 2023-10-19 JP JP2023179961A patent/JP2024010017A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3836922B1 (en) | 2024-08-07 |
| IL280657A (en) | 2021-03-25 |
| WO2020037152A1 (en) | 2020-02-20 |
| JP2024010017A (ja) | 2024-01-23 |
| ES2987802T3 (es) | 2024-11-18 |
| JP2021534160A (ja) | 2021-12-09 |
| CN112584831A (zh) | 2021-03-30 |
| AU2019322889A1 (en) | 2021-03-04 |
| SG11202100880VA (en) | 2021-02-25 |
| US20210315865A1 (en) | 2021-10-14 |
| MX2021001563A (es) | 2021-06-15 |
| PH12021550218A1 (en) | 2021-12-06 |
| EA202190544A1 (ru) | 2021-06-18 |
| BR112021002692A2 (pt) | 2021-05-11 |
| MX2024007642A (es) | 2024-07-04 |
| EP3836922A1 (en) | 2021-06-23 |
| KR20210045423A (ko) | 2021-04-26 |
| EP3836922C0 (en) | 2024-08-07 |
| EP3836922A4 (en) | 2022-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3836922B1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| Maxmen et al. | Psychotropic drugs: Fast facts | |
| JP6090836B2 (ja) | 化学療法剤の抗腫瘍活性増強剤 | |
| US20260014123A1 (en) | Use of riluzole oral disintegrating tablets for treating diseases | |
| Sateia et al. | Efficacy and clinical safety of ramelteon: an evidence-based review | |
| JP7594045B2 (ja) | 薬学的組成物 | |
| WO2023186827A1 (en) | 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression | |
| WO2023186826A1 (en) | 5-meo-dmt for use in the treatment of postpartum depression | |
| Benzer et al. | Case 40-2013: a 36-year-old man with agitation and paranoia | |
| WO2024160392A1 (en) | 5-meo-dmt for use in the treatment of postpartum depression | |
| EA046859B1 (ru) | Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний | |
| JP2010163426A (ja) | ホスホジエステラーゼ５阻害剤とアルギニンを含有する医薬組成物 | |
| Koshy et al. | Thiopentone–midazolam mixture as an induction agent for general anasthesia on ‘in-patients’ | |
| Danyeli et al. | Ketamine in Psychiatric Disorders | |
| EP4499080A1 (en) | 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression | |
| AU2023428136A1 (en) | 5-meo-dmt for use in the treatment of postpartum depression | |
| EP4499079A1 (en) | 5-meo-dmt for use in the treatment of postpartum depression | |
| CA3114867A1 (en) | Compound (8ar,12as,13as)-5,8,8a,9,10,11,12,12a,13,13a-decaidro-3-methoxy-12-(ethylsulphonyl)-6h-isochino [2,1-g] [1,6] naftiridine for use in the treatment of psychoses | |
| MX2007008323A (es) | Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente benzodiazepinico. | |
| JP2010222347A (ja) | Ｐｄｅ５阻害剤及びカルニチンを含有する医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220916 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240722 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240722 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240722 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241003 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250123 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250521 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250521 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250702 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250702 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250808 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250808 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE Effective date: 20251112 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20260223 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260223 |